Cell: Scientists have successfully designed a new muscarinic

Recently, in a research report entitled¬† muscarinic receptors “From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer’s disease” published in the international journal Cell, scientists from the University of Glasgow and other institutions achieved Breakthroughs from the lab to the bedside

In this study, researchers describe for the first time the process of designing a new type of molecule that selectively targets specific receptor proteins in the brain, in both laboratory preclinical and human clinical studies.

The new approach may show potential in developing new drugs to improve cognitive function in the brains of Alzheimer’s patients.¬†There are currently no drugs that can stop or slow the progression of Alzheimer’s disease. However, there are drugs that restore memory loss and improve cognitive function in people with early dementia, but these drugs are often ineffective and produce Certain side effects may limit its application in clinical practice.

The molecule the researchers focused on selectively targets a receptor molecule in the brain called .

The M1-muscarinic acetylcholine receptor (M1 receptor), which plays an important role in the body’s memory and cognitive functions.

  • Role, and subsequent translational medicine studies tested the hypothesis whether molecules such as.
  • These could retain cognitive benefits and lack dose-limiting side effects. Working closely together, the researchers say that although .
  • The M1 receptor is very similar to other types of muscarinic receptors, using .
  • A detailed understanding of the 3D structure of the M1 receptor, they are expected to successfully design .
  • A highly selective modulator Since then, this approach is called structure-based drug design or SBDD.
  • Here, the methods described by the researchers can help design novel molecules with superior properties .
  • That can be used to treat the symptoms of Alzheimer’s disease and other dementias, with potential for preclinical applications.

Investigator Professor Andrew Tobin said: “This is a true laboratory-to-clinical bedside discovery that researchers have been working on for many years now and are delighted to have come together to develop a highly complex drug. Designing methods to improve the treatment of Alzheimer’s patients by activating memory and cognitive centers in the brain.

Related Posts